1. Home
  2. NAMS vs VEON Comparison

NAMS vs VEON Comparison

Compare NAMS & VEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • VEON
  • Stock Information
  • Founded
  • NAMS 2019
  • VEON 1992
  • Country
  • NAMS Netherlands
  • VEON United Arab Emirates
  • Employees
  • NAMS N/A
  • VEON N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • VEON Telecommunications Equipment
  • Sector
  • NAMS Health Care
  • VEON Telecommunications
  • Exchange
  • NAMS Nasdaq
  • VEON Nasdaq
  • Market Cap
  • NAMS 2.5B
  • VEON 2.7B
  • IPO Year
  • NAMS N/A
  • VEON 1996
  • Fundamental
  • Price
  • NAMS $23.60
  • VEON $54.08
  • Analyst Decision
  • NAMS Strong Buy
  • VEON Strong Buy
  • Analyst Count
  • NAMS 9
  • VEON 1
  • Target Price
  • NAMS $41.11
  • VEON $60.00
  • AVG Volume (30 Days)
  • NAMS 844.8K
  • VEON 214.9K
  • Earning Date
  • NAMS 08-06-2025
  • VEON 08-07-2025
  • Dividend Yield
  • NAMS N/A
  • VEON N/A
  • EPS Growth
  • NAMS N/A
  • VEON N/A
  • EPS
  • NAMS N/A
  • VEON 6.56
  • Revenue
  • NAMS $47,140,000.00
  • VEON $4,088,000,000.00
  • Revenue This Year
  • NAMS N/A
  • VEON $7.32
  • Revenue Next Year
  • NAMS N/A
  • VEON $6.68
  • P/E Ratio
  • NAMS N/A
  • VEON $8.50
  • Revenue Growth
  • NAMS 586.97
  • VEON 8.84
  • 52 Week Low
  • NAMS $14.06
  • VEON $25.92
  • 52 Week High
  • NAMS $27.29
  • VEON $59.68
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 67.01
  • VEON 62.72
  • Support Level
  • NAMS $22.00
  • VEON $51.00
  • Resistance Level
  • NAMS $24.82
  • VEON $52.84
  • Average True Range (ATR)
  • NAMS 1.21
  • VEON 2.58
  • MACD
  • NAMS 0.25
  • VEON 0.70
  • Stochastic Oscillator
  • NAMS 77.98
  • VEON 65.24

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About VEON VEON Ltd. ADS

VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.

Share on Social Networks: